file,ref_number,ref_text,doi,doi_url,titleDoi,firstAuthDoi,author_similarity,title_similarity
experiments/gene_essentiality_cancer/ai_messages/high_complexity--PSMB7,[1],"Tomko RJ Jr, Hochstrasser M. 2013. Molecular Biology and Evolution. Molecular architecture and assembly of the eukaryotic proteasome.",10.1146/annurev-biochem-060410-150257,https://doi.org/10.1146/annurev-biochem-060410-150257,Molecular Architecture and Assembly of the Eukaryotic Proteasome,Tomko,100,100
experiments/gene_essentiality_cancer/ai_messages/high_complexity--PSMB7,[2],"Ciechanover A, Kwon YT. 2015. Cell Research. Degradation of misfolded proteins in neurodegenerative diseases: therapeutic targets and strategies.",10.1038/emm.2014.117,https://doi.org/10.1038/emm.2014.117,Degradation of misfolded proteins in neurodegenerative diseases: therapeutic targets and strategies,Ciechanover,100,100
experiments/gene_essentiality_cancer/ai_messages/high_complexity--PSMB7,[3],Adams J. 2004. Cancer Cell. The proteasome: a suitable antineoplastic target.,10.1038/nrc1361,https://doi.org/10.1038/nrc1361,The proteasome: a suitable antineoplastic target,Adams,100,100
experiments/gene_essentiality_cancer/ai_messages/high_complexity--PSMB7,[4],"Vogel C, Marcotte EM. 2012. Nature Reviews Cancer. Insights into the regulation of protein abundance from proteomic and transcriptomic analyses.",10.1038/nrg3185,https://doi.org/10.1038/nrg3185,Insights into the regulation of protein abundance from proteomic and transcriptomic analyses,Vogel,100,100
experiments/gene_essentiality_cancer/ai_messages/high_complexity--PSMB7,[5],"Kisselev AF, van der Linden WA, Overkleeft HS. 2012. Chemical Biology. Proteasome inhibitors: an expanding army attacking a unique target.",10.1016/j.chembiol.2012.01.003,https://doi.org/10.1016/j.chembiol.2012.01.003,Proteasome Inhibitors: An Expanding Army Attacking a Unique Target,Kisselev,100,100
